Kyprolis

Kyprolis

carfilzomib

Manufacturer:

Amgen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Carfilzomib
Indications/Uses
In combination w/ dexamethasone or w/ lenalidomide + dexamethasone for the treatment of patients w/ relapsed or refractory multiple myeloma who have received 1-3 lines of therapy.
Dosage/Direction for Use
In combination w/ lenalidomide & dexamethasone 10-min IV infusion on 2 consecutive days, each wk for 3 wk followed by a 12-day rest period. Starting dose: 20 mg/m2 in cycle 1 on days 1 & 2. If tolerated, escalate the dose to 27 mg/m2 on day 8 of cycle 1. From cycle 13, omit the day 8 & 9 of Kyprolis. Discontinue after cycle 18. Lenalidomide 25 mg is taken orally on days 1-21 & dexamethasone 40 mg by mouth or IV on day 1, 8, 15 & 22 of the 28-day cycles. In combination w/ dexamethasone 30-min IV infusion on 2 consecutive days, each wk for 3 wk followed by a 12-day rest period. Starting dose: 20 mg/m2 in cycle 1 on days 1 & 2. If tolerated, escalate the dose to 56 mg/m2 on day 8 of cycle 1. Dexamethasone 20 mg is taken by mouth or IV on days 1, 2, 8, 9, 15, 16, 22 & 23 of each 28-day cycle. Administer dexamethasone 30 min-4 hr before Kyprolis.
Special Precautions
W/hold treatment for grade 3 or 4 cardiac adverse events, pulmonary HTN. Monitor patients for cardiac failure or cardiac ischemia; evidence of vol overload especially those at risk for cardiac failure; acute renal failure; thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Regularly monitor serum creatinine &/or estimated CrCl; BP & liver enzymes. Patients w/ NYHA class III & IV heart failure, recent MI, conduction abnormalities, angina or arrhythmias uncontrolled by medications. Patients w/ multiple myeloma & high tumor burden should be considered to be at greater risk for tumor lysis syndrome. Ensure patients are well hydrated before administration in cycle 1 & in subsequent cycles as needed. Discontinue treatment in the event of drug-induced pulmonary toxicity; if posterior reversible encephalopathy syndrome is suspected. Stop for grade 3 or 4 dyspnea. Venous thromboembolic events (including DVT & pulmonary embolism), hemorrhage. Administer dexamethasone prior to Kyprolis to reduce the incidence & severity of infusion reactions. Monitor platelet counts frequently during treatment. Combination w/ melphalan & prednisone is not indicated for transplant-ineligible patients w/ newly diagnosed multiple myeloma. May affect ability to drive or operate machinery. Female patients of childbearing potential & male patients must use effective contraceptive measures. Pregnancy (avoid during therapy) & lactation. Childn. Elderly ≥75 yr.
Adverse Reactions
Pneumonia, resp tract infection, pyrexia & pulmonary embolism; MI & upper resp tract infection.
ATC Classification
L01XX45 - carfilzomib ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Kyprolis powd for infusion 60 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in